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FOCUS REVIEW
It was not long ago that I was a medical student at
McGill. I graduated in the class of 1996. 
When I started to do interventional work as a
Cardiology Resident at McGill, we were well into the
era of coronary intervention. Almost every balloon
angioplasty was followed by the implantation of a stent,
which had been shown to improve the immediate and
long-term results of interventional therapy. Life was
becoming easier, dual antiplatelet therapy had emerged
and replaced heparin, dextran, and warfarin which were
initially used to treat every patient with a stent to
prevent acute thrombosis. Our equipment had improved
with better, less bulky balloons that allowed for smaller
caliber guiding catheters and arterial access. This
allowed vascular complications to diminish
significantly. Stents were now being manufactured
attached to balloon catheters decreasing the risk of stent
embolization. There were also a number of
pharmacologic strategies including 2B3A inhibitors
which significantly reduced morbidity in high risk
patients. 
It has been about 8 years since I first scrubbed for an
angioplasty and much has changed. We now know quite
a bit about patient selection, risk management, and the
outcomes after coronary interventions. Regular stents
are still widely in use but drug eluting stents are being
implanted in great numbers. The albatross around the
neck of the stent era of coronary intervention was in-
stent restenosis, an aggressive healing response to the
arterial injury which occurs with both balloon
angioplasty and stent implantation. This process results
in renarrowing of the stented segment over the course of
the first 6 to 9 months of follow up. Restenosis
generally presents as recurrent angina. The risk of
restenosis is related primarily to the presence of
diabetes, and the length and diameter of the stent
implanted. The arrival of drug eluting stents has greatly
diminished the risk of patients developing restenosis
and thereby requiring repeat procedures and suffering
recurrent symptoms. Drug eluting stents have
encouraged a more aggressive percutaneous approach
to the treatment of coronary artery disease in patients
who would have previously been directed toward
surgical revasculariztion. When only bare metal stents
were available, it was hard to justify pursuing an
angioplasty that would almost certainly result in
restensosis. 
Drug eluting stents have been implicated in an
increased risk of stent thrombosis (a much more deadly
acute occlusion of a stented segment) late after the
index procedure. Drugs are likely to delay
endothelialization of the stents by blocking the intense
healing response which causes restenosis. A prolonged
duration of dual antiplatelet therapy with ASA and
Clopidogrel, longer than the 3-6 months recommended
in the initial trials of these therapies, has been suggested
by most interventional practitioners and is thought to be
protective. The most recent analyses have suggested no
increased risk of drug eluting vs bare metal stents in up
to 4 years of follow up after a coronary intervention.
They have also shown no difference in the rate of death
or death/ myocardial infarction in these 2 groups calling
into question the cost effectiveness of drug eluting
stents, which are three to four times the cost of bare
metal stents. Despite the above, I am unaware of any
cardiologist who would not want a DES implanted at
the time of their own angioplasty.
Coronary intervention has been compared to coronary
artery bypass surgery in many populations both with
bare metal stents and with drug eluting stents. In
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ventricular total excursion and peak lengthening rate
was noted in patients undergoing surgery but not in
those undergoing transcatheter closure. It is thought that
this effect was related to poor myocardial preservation
in the operating room, selective damage to longitudinal
muscle fibers which compose the majority of the right
ventricle and poor temperature regulation of the right
ventricle intraoperatively. In our institution catheter
based ASD closure is the preferred method of ASD
closure.
PFO CLOSURE
About thirty percent of the population has a residual
embryologic defect known as a patent foramen ovale.
This connection between the right and left atrium
served to shunt blood between the right atrium and left
during fetal life in utero. During that period, the lungs
were filled with fluid and oxygenated maternal blood
would bypass the right-sided circulation to reach the
fetal organs. PFOs have been implicated in a number of
disease states including cryptogenic stroke, migraine
headache, platypnea orthodeoxia, altitude sickness, and
obstructive sleep apnea. Cryptogenic stroke i.e. stroke
in the absence of classical vascular or cardioembolic
sources, is usually implicated when patients under the
age of 55 years present with prolonged or permanent
neurologic dysfunction. The mechanism has been
attributed to paradoxical embolism through this residual
embryologic intratrial communication in some patients.
There are currently several large randomized trials
underway comparing medical therapy in the form of
ASA or warfarin and percutaneous device closure for
the prevention of recurrent cryptogenic stroke. The jury
is clearly out in this particular patient population
although there is a suggestion from single centre
experiences and meta-analyses that device closure may
offer some protection from recurrent events. Our
practice is to offer patients a complete stroke
investigation including MRI/MRA of the brain,
thrombophilia screening, holter monitoring, and
transesophageal echocardiography when the etiology of
a stroke is unclear. Those patients with cryptogenic
stroke after full investigation will be offered entry into
a randomized trial. Should they not be candidates,
individual consideration of device closure will be
offered after informed consent. 
PDA CLOSURE
Patent ductus arteriosus (PDA) is another residual
embryologic structure that can persist in adults. Large
defects usually present in childhood with heart failure.
A PDA in adults usually manifests as a continuous
murmur; i.e. a murmur which passes through the second
heart sound unchanged. It is usually heard best in the
summary, there is really no evidence of mortality
benefit of one of these treatments versus the other. The
angioplasty patients generally require repeat procedures
versus the surgical patients. Despite an apparent
advantage of surgery, most patients who have been
given a full informed consent choose angioplasty for its
less invasive properties and the shorter recovery times
required.
A discussion of coronary disease could easily fill
volumes with data, conjecture and opinion. Although
coronary artery disease by far occupies the most time of
any cardiac interventional program, many other
interventions are currently being performed to treat
cardiac disease and will be the focus of the remainder of
this discussion.
Structural heart disease is an explosive area of
cardiovascular interventional cardiology and can be
alternatively defined as non-coronary cardiac
intervention. Interventions in structural heart disease
occupy increasing time at many scientific meetings and
are seeing a rise in the number of practitioners carrying
out these interventions.
ASD CLOSURE
The skills to perform structural procedures are based
in pediatric cardiology and interventional radiology. By
far the most common intervention is atrial septal defect
closure. Patients born with a significant atrial septal
defect go on to develop right ventricular dilatation and
manifest symptoms or exercise intolerance and cardiac
rhythm disturbances. As decades go by, the pulmonary
pressure may rise to moderate levels. Symptoms worsen
over time in relation to the stiffening of the left ventricle
with age which promotes increased left to right flow
through these defects. Probably the best marker of a
significant defect is right ventricular enlargement.
Surgery for atrial septal defects has been carried out
since the 1950’s. The catheter-based solutions came into
common usage in the mid to late 1990’s. 
The method of closing any intracardiac defect with
any device is similar. A device, usually with 2 discs or
umbrellas is attached to a delivery cable. By virtue of
the design or mechanical properties of the device it can
be advanced through a narrow tube or catheter, usually
less than 3 mm in diameter. The catheter is advanced
across the defect and one side of the device is released.
The catheter and exposed disc or umbrella are
withdrawn until they make contact with the defect and
then the other disk is exposed on the opposite side of the
hole providing closure. The device can then be released
from the delivery system. Using this method, atrial
septal defects up to 40 mm in diameter can be closed.
Transcatheter ASD closure offers benefits over
surgery. In an elegant study by Dhillon, decreased right154 McGill Journal of Medicine 2007
left infraclavicular space and can be missed if not
specifically listened for. The indication for PDA closure
is the presence of an audible murmur and the reason for
closure is to prevent endarteritis which results in a
systemic bacteremeia. The transcatheter procedure is
technically uncomplicated and involves crossing over
the defect from the pulmonary artery and implanting
either a coil or device in the ductus to promote
thrombosis and occlusion. 
PROCEDURAL IMAGING
The procedure for closure of ASDs, PFO and PDAs
are well established and can usually be accomplished in
well less than an hour. ASD closure procedures in our
institution are performed with the use of fluoroscopy as
well as intracardiac echo (ICE) guidance. Many sites
around the world continue to close ASDs with patients
under general anesthesia and transesophageal echo
guidance. The advantages of intracardiac echo (a ten
French or 3.33 mm diameter catheter) include:
increased patient comfort, freedom from general
anesthesia and the required recovery period,
independence from busy echocardiographers, and
unique views of the septum not available with TEE.
Most importantly, the use of ICE requires and promotes
the development of the echo skills of the operator who
is ultimately responsible. Knowledge of echo anatomy
allows translation to other structural heart disease
interventions. PFO closure is generally performed with
the use of fluoroscopy alone as is PDA closure.
There are a number of devices available for
intracardiac use each with their own advantages and
disadvantages. Probably the most relevant factor in
device selection is operator comfort and knowledge of
the system in question. There are particular anatomic
situations where one device’s features are clearly
advantageous, arguing for operators to have a working
knowledge of multiple devices or systems. Low volume
operators in structural heart disease intervention are
clearly a liability and while the optimal number of
annual procedures is not well defined, it is quite clear
that high volume operators are likely to have better
outcomes and broader experience than low volume
operators.
OTHER INTERVENTIONS 
While the three lesions described above constitute the
bulk of adult structural heart disease practice, there are
countless lesions that require treatment in this patient
population on a less frequent basis. They include stent
placement for coarctation of the aorta, stenting of
stenotic pulmonary arteries, pulmonary or systemic
veins, surgically created baffles used to treat
transposition of the great arteries, or conduits from the
ventricles to the great arteries to bypass inoperable
subvalvular obstruction. We are often called upon to
occlude venous or arterial collateral vessels from the
aorta or great veins as well as pulmonary arteriovenous
malformations. Coronary fistula closure is a regularly
performed procedure. Pulmonary and aortic balloon
valvuloplasty are not infrequently performed
procedures for stenotic valves. With experience in
device use and sophisticated techniques, closure of
perivalvular leaks around mechanical valves, aortoatrial
fistulas, aortic pseudoaneurysms, and ventricular septal
defects of both congenital and post myocardial
infarction etiology is possible. 
TRANSCATHETER VALVE THERAPIES
Whereas as recently as five years ago, catheter-based
treatment of valvular heart disease consisted only of
balloon valvuloplasty, our present armamentarium of




The earliest clinical experience with percutaneous
heart valve therapy was for the treatment of pulmonary
regurgitation. In certain patients with congenital heart
disease, particularly those with Tetralogy of Fallot, a
valved conduit from the right ventricle has been used as
part of the definitive repair in patients with inoperable
right ventricular outflow tract disease. Unfortunately,
the natural history of these conduits is one of
progressive regurgitation or stenosis or both. Conduit
regurgitation/stenosis leads to right ventricular dilation
and dysfunction, resulting in progressive symptoms of
exercise intolerance, arrhythmia and right sided heart
failure. Philip Bonhoeffer pioneered a technique which
involved harvesting a bovine jugular venous valve and
suturing it into a stent that could be placed into a
surgical conduit to eliminate conduit regurgitation and
improve stenosis. This therapy has the advantage of
increasing the time between major cardiac operations in
children with certain forms of congenital heart disease.
The Medtronic Melody™ pulmonary valve is the
product of this endeavour and has been implanted in
well over 200 patients. I was fortunate to implant the
first of these valves in North America with Dr. Lee
Benson at the Hospital for Sick Children several years
ago. 
The challenge at present is to be able to offer
percutaneous pulmonary valve therapy not only to the
relatively few patients with conduits, but to the broader
population of patients with congenital heart disease who
have severe native pulmonary regurgitation, a common
lesion. The challenge with the present technology is thatInterventional Cardiology 155 Vol. 10  No. 2
the largest bovine jugular venous valves are 22mm in
diameter when fully expanded. Many native outflow
tracts are significantly larger than this. There are a
variety of strategies being considered to deal with this
problem. For example, a “docking station” has been
proposed: a larger “reducing” stent would be implanted
first to decrease the diameter of a large native outflow
tract. A smaller valve could then be implanted within.
Only time will tell whether this will be successful. A
second manufacturer has also produced a bioprosthetic
valve that has been implanted in humans. Edwards
Lifesciences has implanted the Harmony™ valve in the
pulmonic position in 4 patients. This valve is a bovine
pericardial bioprosthesis that at present comes in 2 sizes
measuring 23 and 26 mm. 
TRANSCATHETER AORTIC VALVE
SOLUTIONS
Potentially the largest group of patients in need of a
valvular heart disease solution is those with severe
aortic stenosis. Aortic stenosis is generally a disease of
the elderly. Concomitant coronary artery disease,
pulmonary, renal, hepatic and cerebrovascular disease
are also prevalent in this population. When expected
surgical mortality exceeds 15%, both patients and
surgeons are hesitant to accept and offer therapy
respectively. The possibility of deploying a valve in a
stent that could displace the patient’s native valve is an
attractive alternative that has been hypothesized since
the early 1980s. There are 2 potential routes to deliver
an aortic valve on a stent. The antegrade approach,
which involves a transeptal puncture and passage of the
valve from the right atrium to the left atrium and
through the left ventricle, has been abandoned. This
route has been implicated in injury to the mitral valve
and is technically demanding. A potentially less
complicated approach is to deliver the valve via a
retrograde approach, which involves passing the valve
from the femoral artery around the aortic arch and into
position.
At present there are 2 protheses that have been
implanted in humans; Edwards’ Sapien ™ valve and
Corevalve’s Revalving™ system are two different
approaches to the challenge of aortic stenosis. The
Sapien ™ valve is mounted on a balloon, and deployed
with a single balloon inflation during rapid pacing of the
right ventricle to reduce cardiac output. The limitation
of this valve at present is its large profile, a 23 mm valve
and a 26 mm valve are available and require a 22 french
and 26 french sheath to deliver respectively. In the
elderly with aortic stenosis, it is a challenge to find
patients with iliac arteries of between 8 and 9 mm
required to deliver this valve. A novel alternative, using
a minimally invasive surgical technique, involves the
performance of a left mini thoracotomy for delivery of
the valve through the apex of a beating heart. Several
hundred of these transapical procedures have been
performed with quite reasonable results allowing for the
infirmity of those patients who require this approach.
The Corevalve Revalving™ prosthesis is now
approved in Europe with an 18 french system. The
lower profile is achieved primarily through the use of a
self-expanding stent platform as opposed to a balloon
expandable system. 
Over 20 other companies are working on the
development of percutaneous aortic valve technologies.
Key features of the next generation of technologies
include the ability to reposition, remove, and exchange
a new valve and the ability to deploy them through an
arterial access that allows the majority of eligible
patients to be treated. The ideal valve would have a low
risk of infection, be easy to use, and not require
anticoagulation. The future is bright and many new
therapies are near human implantation.
TRANSCATHETER MITRAL VALVE
SOLUTIONS
The mitral valve is by far the most difficult valve to
treat percutaneously. While the aortic and pulmonary
systems  are fairly simple consisting of a relatively fixed
annulus with attached leaflets, the mitral valve is of far
greater complexity. For the mitral valve to function
correctly, a synchronized effort on behalf of the mitral
leaflets, annulus, chordae, papillary muscles and the
walls of the left ventricle is required. 
There are a number of strategies hypothesized to
impact the regurgitant mitral valve. The most mature
technology already in a randomized trial vs surgery is
the Evalve MitraClip™. This technology is implanted
using a specialized delivery catheter via a transeptal
approach using primarily transesophageal echo for
guidance. The clip is implanted on the A2 and P2
leaflets (mid portion of each mitral leaflet) for
pathology ranging from functional, prolapse, flail and
ischemic mitral insufficiency. The initial results are
promising, demonstrating the ability to reduce mitral
insufficiency from 4+ to <2+ in a majority of patients.
The procedure is technically demanding but with
experience, procedure times are falling as results
improve.
The “leaflet” approach to mitral repair is but a single
avenue of therapy. Several companies have utilized the
relationship of the coronary sinus to the mitral valve
annulus to advantage. By implanting a device which
cinches the coronary sinus, it is possible to reduce the
size of the annulus of the mitral valve. This mechanism
for valve dysfunction occurs primarily in those patients
with congestive heart failure and a dilated mitral valve156 McGill Journal of Medicine 2007
annulus. Early results are promising but whether or not
sufficient MR reduction will occur with this type of
therapy remains to be seen. A second obstacle is the
variable relationship of the coronary sinus to the
annulus and circumflex coronary artery. 
Mitralign™ is a therapy designed to be delivered
from a retrograde access. This technology employs a
direct suture annuloplasty delivered from the inside of
the ventricle. The first human procedure is expected
soon. 
Reshaping of the heart muscle into a more favorable
geometric configuration for the mitral valve is the aim
of the Myocor Coapsys system. This therapy, which has
been used surgically, is being adapted as a percutaneous
procedure. Access is obtained to the pericardial space,
and two anchors, joined by a tether which runs through
the ventricle, are implanted on the outer surface of the
anterior and posterior surface of the left ventricle. The
system aims to reduce the antero-posterior dimension of
the ventricle to reapproximate mitral valve leaflets that
no longer coapt because of annular dilation. Another
innovative technology created by Ample Medical™
uses a novel technique to deliver a suture from the
coronary sinus to an atrial septal occlusion device.
Under TEE guidance, the AP diameter of the annulus
can be reduced by tightening the suture and
reapproximating mitral valve leaflets in a dilated
annulus.
A NOTE OF CAUTION 
The success of transcatheter structural heart disease
therapies has been the ability to repair intracardiac
defects that once required surgery in a minimally
invasive fashion. In high-risk patients these therapies
are readily accepted. In patients of low operative risk
we must constantly re-examine and be critical of
transcatheter therapies with the availability of excellent
surgical therapies with long-term track records.
Although device closure of atrial septal defects is the
standard of care, we have learned the importance of
patient selection to avoid device erosion which almost
uniformly leads to tamponade or important
complications. Similarly, although the closure of
perimembranous VSDs in children is almost uniformly
successful, there is a small, but present, risk of heart
block requiring permanent pacing. A pacemaker implant
in a small child will require multiple revisions with
attendant morbidity. A healthy respect for the
complications of new and innovative therapy is critical
for interventionalists. Careful evaluation, monitoring
and reporting of outcomes of these new therapies are
critical for further advancement and insight into ideal
patient selection. A referral to a structural heart disease
interventionalist should be a true consulting process
where the relative indications for therapy are explored
and the merits of conventional surgery vs a catheter
intervention are discussed overtly with the patient.
CONCLUSION
The future of transcatheter therapies for structural
heart disease is bright. There are a paucity of
practitioners at present who are able to deliver these
therapies in adult patients. As this subspecialty of
cardiology evolves and matures, it will have a profound
impact on the natural history of our patients and their
families. It will only be through partnering with our
surgical colleagues that we will optimize outcomes and
improve decision-making. Collaboration with industry
to modify, improve and develop future therapies is a
critical part of the future. In 1996, when I graduated
from medical school, many of the therapies I have
described had not been conceived.
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